Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy

Inclusion Criteria:

Subjects have metastatic TNBC

Disease suitable for analysis from either (a) or (b) below:

(a) Research biopsy

Tumor tissue, which can include bone disease, as determined by physical exam or imaging (as assessed by a trained specialist in radiology)
Must be collected before the subject receives treatment with a drug they have not received previously

(b) Standard of care biopsy

Tumor tissue available from a previous biopsy as standard of care (to be determined by the principal investigator [PI] or his designee)
Must have been collected before subject receives treatment with a drug they have not received previously
May begin treatment either after enrollment or within several weeks prior to enrollment
Subjects must be medically fit and willing to undergo repeated tissue biopsies or surgical procedures to get tumor tissue
Procedure-specific signed informed consent prior to initiation of any study-related procedures
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (or a Karnofsky performance status of >= 50%)
Agree to allow their de-identified clinical and laboratory data to be posted to publicly available databases such as database of Genotypes and Phenotypes (dbGaP)

Exclusion Criteria:

Bevacizumab treatment within 4 weeks prior to biopsy
Anticoagulation therapy, unless reversed at the time of biopsy
The enrolling study oncologist has decided that the subject is not fit enough to undergo repeated tissue biopsies
Presence of a condition or abnormality that in the opinion of the enrolling investigator would compromise the safety of the subject or the quality of the data
Significant bleeding disorder
Known brain metastases that have not or will not be treated
Subjects with a life expectancy of less than 6 months
Prisoners
Inability to give informed consent